263 related articles for article (PubMed ID: 19136028)
21. Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M; Lopiano L
Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
[TBL] [Abstract][Full Text] [Related]
22. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
Kramer ML; Behrens C; Schulz-Schaeffer WJ
Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
[TBL] [Abstract][Full Text] [Related]
23. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease.
McNaught KS; Olanow CW
Neurobiol Aging; 2006 Apr; 27(4):530-45. PubMed ID: 16207501
[TBL] [Abstract][Full Text] [Related]
24. Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy.
Follmer C
Expert Rev Neurother; 2014 Jun; 14(6):703-16. PubMed ID: 24852232
[TBL] [Abstract][Full Text] [Related]
25. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
26. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors.
Kao SY
Biochem Biophys Res Commun; 2009 Jul; 385(3):434-8. PubMed ID: 19470380
[TBL] [Abstract][Full Text] [Related]
27. Protein degradation, aggregation, and misfolding.
Cuervo AM; Wong ES; Martinez-Vicente M
Mov Disord; 2010; 25 Suppl 1():S49-54. PubMed ID: 20187257
[TBL] [Abstract][Full Text] [Related]
28. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
Luk KC; Hyde EG; Trojanowski JQ; Lee VM
Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
[TBL] [Abstract][Full Text] [Related]
29. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation.
Shaikh S; Nicholson LF
J Neurosci Res; 2008 Jul; 86(9):2071-82. PubMed ID: 18335520
[TBL] [Abstract][Full Text] [Related]
30. Dynamic modelling of protein and oxidative metabolisms simulates the pathogenesis of Parkinson's disease.
Cloutier M; Wellstead P
IET Syst Biol; 2012 Jun; 6(3):65-72. PubMed ID: 22757585
[TBL] [Abstract][Full Text] [Related]
31. Modeling proteasome dynamics in Parkinson's disease.
Sneppen K; Lizana L; Jensen MH; Pigolotti S; Otzen D
Phys Biol; 2009 May; 6(3):036005. PubMed ID: 19411740
[TBL] [Abstract][Full Text] [Related]
32. Ubiquitin-proteasome system and Parkinson's disease.
Olanow CW; McNaught KS
Mov Disord; 2006 Nov; 21(11):1806-23. PubMed ID: 16972273
[TBL] [Abstract][Full Text] [Related]
33. Role of autophagy and proteasome degradation pathways in apoptosis of PC12 cells overexpressing human alpha-synuclein.
Yang F; Yang YP; Mao CJ; Cao BY; Cai ZL; Shi JJ; Huang JZ; Zhang P; Liu CF
Neurosci Lett; 2009 May; 454(3):203-8. PubMed ID: 19429084
[TBL] [Abstract][Full Text] [Related]
34. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease.
Pan T; Kondo S; Le W; Jankovic J
Brain; 2008 Aug; 131(Pt 8):1969-78. PubMed ID: 18187492
[TBL] [Abstract][Full Text] [Related]
35. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Yokochi M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
[TBL] [Abstract][Full Text] [Related]
36. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages.
Ichibangase T; Saimaru H; Takamura N; Kuwahara T; Koyama A; Iwatsubo T; Imai K
Biomed Chromatogr; 2008 Mar; 22(3):232-4. PubMed ID: 17939164
[TBL] [Abstract][Full Text] [Related]
37. Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease.
Wu G; Yan B; Wang X; Feng X; Zhang A; Xu X; Dong H
J Neurol Sci; 2008 Aug; 271(1-2):168-73. PubMed ID: 18495164
[TBL] [Abstract][Full Text] [Related]
38. In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease.
Yeager MP; Coleman RA
J Neurosci Methods; 2010 Apr; 188(1):151-64. PubMed ID: 20144654
[TBL] [Abstract][Full Text] [Related]
39. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
Naoi M; Maruyama W; Shamoto-Nagai M; Riederer P
J Neural Transm (Vienna); 2024 Jun; 131(6):639-661. PubMed ID: 38196001
[TBL] [Abstract][Full Text] [Related]
40. A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
Sasidharakurup H; Melethadathil N; Nair B; Diwakar S
OMICS; 2017 Aug; 21(8):454-464. PubMed ID: 28816645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
